-
Taro to hold meetings for approval of merger with Sun Pharmaceutical Industries
If the merger is completed, Taro will become a privately held company and its shares will no longer be listed on the NYSE. -
Upsher-Smith previews expansion of rare disease portfolio at 2024 AAN annual meeting
Upsher-Smith has broadened its offerings to include Vigadrone (vigabatrin) Tablets, 500 mg. Torpenz Tablets, a branded-generic everolimus tablet, will soon be available to prescribers and patients.